Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates

Core Insights - Corcept Therapeutics (CORT) reported quarterly earnings of $0.29 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, but down from $0.32 per share a year ago, resulting in an earnings surprise of +26.09% [1] - The company posted revenues of $194.43 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.73%, compared to $163.8 million in the same quarter last year [2] - Corcept shares have increased approximately 38.7% year-to-date, significantly outperforming the S&P 500's gain of 8.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $242.34 million, and for the current fiscal year, it is $1.39 on revenues of $899.03 million [7] - The estimate revisions trend for Corcept was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Corcept belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - ARS Pharmaceuticals, Inc. is another company in the same industry, expected to report a quarterly loss of $0.41 per share, with revenues projected to be $15.12 million, reflecting a significant year-over-year increase [9]